La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Voyager Therapeutics Gestion

Gestion contrôle des critères 0/4

Informations clés

Al Sandrock

Directeur général

US$3.2m

Rémunération totale

Pourcentage du salaire du PDG	19.7%
Durée du mandat du directeur général	2.4yrs
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	2.4yrs
Durée moyenne du mandat des membres du conseil d'administration	5.2yrs

Mises à jour récentes de la gestion

Recent updates

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 09

Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Aug 08

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Jun 05

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Mar 15

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Mar 08

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Mar 04

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Jan 04

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target

Oct 04

Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

May 12

Voyager Does A Reboot After First Generation Failures

Mar 25

Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky

Feb 07

Voyager Therapeutics: Another Year, Another Deal

Nov 21

Analyse de la rémunération des PDG

Comment la rémunération de Al Sandrock a-t-elle évolué par rapport aux bénéfices de Voyager Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	US$9m
Mar 31 2024	n/a	n/a	-US$3m
Dec 31 2023	US$3m	US$624k	US$132m
Sep 30 2023	n/a	n/a	US$52m
Jun 30 2023	n/a	n/a	US$96m
Mar 31 2023	n/a	n/a	US$99m
Dec 31 2022	US$7m	US$525k	-US$46m

PDG

Al Sandrock (66 yo)

2.4yrs

Titularisation

US$3,172,433

Compensation

Dr. Alfred W. Sandrock Jr., also known as Al, M.D., Ph D., served as Director at Verge Analytics, Inc. since February 2022. He serves as Member of Scientific Advisory Board at Camp4 Therapeutics Corporatio...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Alfred Sandrock	President	2.4yrs	US$3.17m	0.12% $ 418.5k
Robin Swartz	COO & Acting Chief Business Officer	no data	US$1.38m	0.062% $ 224.3k
Jacquelyn Sandell	Chief Legal Officer	1.1yrs	US$1.91m	0% $ 0
Krystof Bankiewicz	Founder	no data	pas de données	pas de données
Guangping Gao	Founder & Member of Scientific Advisory Board	no data	pas de données	pas de données
Mark Kay	Founder	no data	pas de données	pas de données
Phillip Zamore	Founder & Member of Scientific Advisory Board	no data	pas de données	pas de données
Nathan Jorgensen	Chief Financial Officer	less than a year	pas de données	pas de données
Todd Carter	Chief Scientific Officer	1.9yrs	pas de données	0.16% $ 583.6k
Michelle Smith	Chief Human Resources Officer	3.9yrs	pas de données	pas de données
Maria Lopez-Bresnahan	Senior Vice President of Translational Medicine & Clinical Development	4yrs	pas de données	pas de données
Trista Morrison	Chief Corporate Affairs Officer & Chief of Staff to the CEO	2.6yrs	pas de données	pas de données

2.4yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Alfred Sandrock	President	2.5yrs	US$3.17m	0.12% $ 418.5k
Guangping Gao	Founder & Member of Scientific Advisory Board	no data	pas de données	pas de données
Phillip Zamore	Founder & Member of Scientific Advisory Board	no data	pas de données	pas de données
Dinah Sah	Consultant & Member of Scientific Advisory Board	5.2yrs	US$1.81m	pas de données
James Arthur Geraghty	Independent Director	10.6yrs	US$263.78k	0.10% $ 363.6k
Glenn Pierce	Independent Director	7.6yrs	US$248.78k	0.040% $ 145.1k
Steven Hyman	Independent Director	8.9yrs	US$255.78k	0% $ 0
Michael Higgins	Independent Chairman of the Board	9.1yrs	US$281.28k	0.057% $ 208.5k
Catherine Mackey	Independent Director	2.1yrs	US$250.78k	0% $ 0
David Liu	Member of Scientific Advisory Board	no data	pas de données	pas de données
Grace Colon	Independent Director	1.6yrs	US$432.23k	0% $ 0
Nancy Vitale	Independent Director	3.9yrs	US$255.28k	0% $ 0

5.2yrs

Durée moyenne de l'emploi

66yo

Voyager Therapeutics Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024

Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

President recently sold US$119k worth of stock

President notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Recent updates

Consensus revenue estimates increase by 42%

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 2500 Growth Index

Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Consensus revenue estimates increase by 29%

Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER™?-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting

Voyager Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Investor sentiment improves as stock rises 16%

Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

President recently sold US$119k worth of stock

President notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Consensus revenue estimates fall by 21%

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Investor sentiment improves as stock rises 18%

President recently sold US$97k worth of stock

President notifies of intention to sell stock

Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research

New minor risk - Share price stability

Voyager Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Voyager Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Chief Financial Officer recently sold US$95k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

Chief Science Officer notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 25%

Price target increased by 9.8% to US$11.17

Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

President recently sold US$58k worth of stock

Chief Operating Officer recently sold US$126k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$8.20

Voyager Therapeutics, Inc. Appoints Grace E. Colón, Ph.D., to Its Board of Directors, Effective on January 1, 2023

Consensus revenue estimates increase by 170%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Voyager Therapeutics, Inc Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target

Consensus forecasts updated

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO, Effective September 19, 2022

Voyager Therapeutics hires new finance chief

Consensus forecasts updated

Consensus revenue estimates fall by 86%

Second quarter 2022 earnings released: US$0.50 loss per share (vs US$0.80 loss in 2Q 2021)

Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

Voyager Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022